Plastic Bronchitis Clinical Trial
Official title:
The Efficacy and Safety of Sirolimus for Plastic Bronchitis：a Pilot Study
There is no confirmed drug therapy for plastic bronchitis. The study wish to test the effectiveness and safety of sirolimus (rapamycin) in patients with lymphatic plastic bronchitis.
Plastic bronchitis is a rare respiratory disorder characterized by formation of gelatinous or rigid cast of bronchial tree. Confirmed drug therapy for plastic bronchitis is lacking. Recently, part of plastic bronchitis has been found to have dysfunction of lymphatic circulation in the lung. Pulmonary lymphatic perfusion syndrome (PLPS) is regarded as a major mechanism of lymphatic plastic bronchitis. Sirolimus (rapamycin) has not been studied in plastic bronchitis, however, it has been shown effective in several lymphatic disorders, such as lymphangioleiomyomatosis, generalized lymphatic anomaly (GLA) including lymphangiomatosis, etc. We wish to test the effectiveness of sirolimus in lymphatic plastic bronchitis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02315898 -
Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
|
Phase 2 | |
| Terminated |
NCT01663948 -
International Plastic Bronchitis Registry
|
||
| Completed |
NCT04163653 -
Lymphatic Morphology of Fontan Patients
|